| Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ... Cell 173 (3), 581-594. e12, 2018 | 780 | 2018 |
| Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ... Cell 173 (3), 595-610. e11, 2018 | 621 | 2018 |
| Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ... Cell 173 (3), 611-623. e17, 2018 | 524 | 2018 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 454 | 2017 |
| Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis KE Rusthoven, SF Hammerman, BD Kavanagh, MJ Birtwhistle, M Stares, ... Acta oncologica 48 (4), 578-583, 2009 | 184 | 2009 |
| Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution M Kovac, C Navas, S Horswell, M Salm, C Bardella, A Rowan, M Stares, ... Nature communications 6 (1), 6336, 2015 | 137 | 2015 |
| Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution R Fisher, S Horswell, A Rowan, MP Salm, EC de Bruin, S Gulati, ... Genome biology 15, 1-15, 2014 | 86 | 2014 |
| How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma? A Soultati, M Stares, C Swanton, J Larkin, S Turajlic Current Opinion in Urology 25 (5), 358-366, 2015 | 44 | 2015 |
| Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer M Stares, TE Ding, C Stratton, F Thomson, M Baxter, H Cagney, ... ESMO open 7 (2), 100445, 2022 | 39 | 2022 |
| Hypoalbuminaemia as a prognostic biomarker of first-line treatment resistance in metastatic non-small cell lung cancer M Stares, A Swan, K Cumming, TE Ding, J Leach, C Stratton, F Thomson, ... Frontiers in Nutrition 8, 734735, 2021 | 31 | 2021 |
| Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis M Stares, K Purshouse, G Knowles, R Haigh, J Irvine, A Gatenby, ... British Journal of Cancer 125 (11), 1503-1510, 2021 | 11 | 2021 |
| Primary succession of Bifidobacteria drives pathogen resistance in neonatal microbiota assembly Y Shao, C Garcia-Mauriño, S Clare, NJR Dawson, A Mu, A Adoum, ... Nature Microbiology 9 (10), 2570-2582, 2024 | 8 | 2024 |
| Immune-related adverse events, biomarkers of systemic inflammation, and survival outcomes in patients receiving pembrolizumab for non-small-cell lung cancer G Raynes, M Stares, S Low, D Haron, H Sarwar, D Abhi, C Barrie, B Laird, ... Cancers 15 (23), 5502, 2023 | 8 | 2023 |
| Optimising outcomes in non small cell lung cancer: targeting cancer cachexia I Phillips, M Stares, L Allan, J Sayers, R Skipworth, B Laird Frontiers in Bioscience-Landmark 27 (4), 129, 2022 | 8 | 2022 |
| Real-world impact of SABR on stage I non-small-cell lung cancer outcomes at a scottish cancer centre M Stares, G Lewis, M Vallet, A Killean, G Tramonti, A Patrizio, M Mackean, ... Cancers 15 (5), 1431, 2023 | 7 | 2023 |
| Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1≥ 50% progressing on first-line pembrolizumab M Stares, E Doyle, S Chapple, G Raynes, J MacDonald, C Barrie, B Laird, ... Lung Cancer 189, 107497, 2024 | 5 | 2024 |
| Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre M Stares, V Chauhan, J Moudgil‐Joshi, QG Kong, J Malik, ... Cancer Medicine 12 (5), 5255-5264, 2023 | 5 | 2023 |
| A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin M Stares, R Patton, G Knowles, R Haigh, C Barrie, L Dobbs, D McMillan, ... European Journal of Cancer 139, 1-9, 2020 | 5 | 2020 |
| ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre-and post-operative therapy in metastatic renal cell carcinoma. M Stares, S Turajlic, AJS Furness, K Joshi, D Nicol, ME Gore, ... Journal of Clinical Oncology 34 (15_suppl), TPS4583-TPS4583, 2016 | 4 | 2016 |
| Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer TG Ding, F Thomson, C Stratton, K Cumming, C Barrie, K Maclennan, ... Lung Cancer 156, S43, 2021 | 3 | 2021 |
